Next Article in Journal
Surgical Management of Spinal Disorders in People with Mucopolysaccharidoses
Next Article in Special Issue
The Relationships Between Stress, Mental Disorders, and Epigenetic Regulation of BDNF
Previous Article in Journal
High Dosage Lithium Treatment Induces DNA Damage and p57Kip2 Decrease
Previous Article in Special Issue
Brain-Derived Neurotrophic Factor and Diabetes
Open AccessReview

BDNF as a Promising Therapeutic Agent in Parkinson’s Disease

1
Mossakowski Medical Research Centre Polish Academy of Sciences, 02-106 Warsaw, Poland
2
Nencki Institute of Experimental Biology Polish Academy of Sciences, 02-093 Warsaw, Poland
3
Faculty in Biala Podlaska, Jozef Pilsudski University of Physical Education in Warsaw, 21-500 Warszawa, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(3), 1170; https://doi.org/10.3390/ijms21031170
Received: 19 December 2019 / Revised: 17 January 2020 / Accepted: 6 February 2020 / Published: 10 February 2020
(This article belongs to the Special Issue Brain-Derived Neurotrophic Factor 2020)
Brain-derived neurotrophic factor (BDNF) promotes neuroprotection and neuroregeneration. In animal models of Parkinson’s disease (PD), BDNF enhances the survival of dopaminergic neurons, improves dopaminergic neurotransmission and motor performance. Pharmacological therapies of PD are symptom-targeting, and their effectiveness decreases with the progression of the disease; therefore, new therapeutical approaches are needed. Since, in both PD patients and animal PD models, decreased level of BDNF was found in the nigrostriatal pathway, it has been hypothesized that BDNF may serve as a therapeutic agent. Direct delivery of exogenous BDNF into the patient’s brain did not relieve the symptoms of disease, nor did attempts to enhance BDNF expression with gene therapy. Physical training was neuroprotective in animal models of PD. This effect is mediated, at least partly, by BDNF. Animal studies revealed that physical activity increases BDNF and tropomyosin receptor kinase B (TrkB) expression, leading to inhibition of neurodegeneration through induction of transcription factors and expression of genes related to neuronal proliferation, survival, and inflammatory response. This review focuses on the evidence that increasing BDNF level due to gene modulation or physical exercise has a neuroprotective effect and could be considered as adjunctive therapy in PD. View Full-Text
Keywords: brain-derived neurotrophic factor; neurodegeneration; Parkinson’s disease; physical exercise; neuroprotection; PD therapy brain-derived neurotrophic factor; neurodegeneration; Parkinson’s disease; physical exercise; neuroprotection; PD therapy
Show Figures

Figure 1

MDPI and ACS Style

Palasz, E.; Wysocka, A.; Gasiorowska, A.; Chalimoniuk, M.; Niewiadomski, W.; Niewiadomska, G. BDNF as a Promising Therapeutic Agent in Parkinson’s Disease. Int. J. Mol. Sci. 2020, 21, 1170.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop